IlluminOss system successfully used on R.I. patient

ROBERT RABINER, founder of IlluminOss Medical,said they have
ROBERT RABINER, founder of IlluminOss Medical,said they have "had tremendously successful results treating complex fractures with the IlluminOss System internationally and are excited to now begin applying it to the treatment of patients with impending and pathologic fractures in our first U.S. trial." / PBN FILE PHOTO/RUPERT WHITELEY

EAST PROVIDENCE – IlluminOss Medical has announced that its first patient at Rhode Island Hospital has been successfully treated as part of its Lightfix clinical trial.
The company, a commercial stage medical device company focused on minimally invasive orthopedic fracture repair, said the patient was treated by Dr. Richard Terek.
“IlluminOss’ technology promises to fulfill an important clinical need for patients with metastatic bone disease,” Terek, an attending orthopedic surgeon at The Miriam and Rhode Island hospitals and chief of orthopaedic surgery at the Providence VA Medical Center, said in a statement.
“In cases of metastatic carcinoma the cancer often destroys so much of the bone that it is difficult to achieve stabilization with a conventional rod. IlluminOss offers a less invasive approach designed to make more effective implants possible. I’m very satisfied with the results in this case to date and look forward to offering this treatment option to more patients who qualify,” Terek said.

The IlluminOss system has been used in the treatment of more than 1,000 patients in Europe, where it is commercially available and has been in use since 2010. It allows surgeons to create a first-of-its-kind patient-conforming implant that provides almost instant internal support of bones affected by cancer.

Fractures are repaired utilizing a light-curable polymer, contained within a balloon catheter, the company said.

The company said benefits of the system often include smaller incisions, shorter procedure times and a quicker post-procedure patient mobility, as well as shorter hospital stays and lower complication rates.

- Advertisement -

“We’ve already seen many successful results in the treatment of patients around the world but, as a Rhode Island–based company, there is something particularly gratifying to us personally about treating our first patient here,” Robert Rabiner, president of IlluminOss Medical, said. “It’s been a pleasure to work with Dr. Terek and his team and we commend Rhode Island Hospital on the first-rate infrastructure and support staff it has in place to participate in trials and offer cutting-edge medical advancements to its patients.”
IlluminOss is funded by Foundation Medical Partners, New Leaf Venture Partners, Tekla Capital Management, Life Sciences Partners, SR One, Longwood Fund, Excel Venture Management, Pappas Ventures, Mieza Capital and the Slater Technology Fund.
“IlluminOss is well positioned to have a revolutionary impact on the orthopedic device space and is a true testament to Rhode Island’s innovation economy,” Richard Horan, managing director at the Slater Technology Fund, said. “IlluminOss has grown its staff, increased its facilities and is well on its way toward seeking approval from the FDA to offer its technology commercially in the U.S. It’s a real Rhode Island success story and certainly a company to watch.”
IlluminOss is currently enrolling patients at other U.S. surgical sites in the Lightfix clinical trial.

For information about this trial, visit www.ClinicalTrials.gov.

No posts to display